<DOC>
	<DOCNO>NCT01317641</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics ODM-201 patient castrate resistant prostate cancer .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study ODM-201 Castrate Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Written inform consent Histologically confirm adenocarcinoma prostate Ongoing androgen deprivation therapy LHRH analogue antagonist bilateral orchiectomy Progressive metastatic disease Adequate bone marrow , hepatic , renal function Known metastases brain History malignancy within previous 5 year Known gastrointestinal disease procedure affect absorption Not able swallow study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>